A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

NCT05179239 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor develops strategy adjustment

Conditions

Cervical Cancer

Interventions

DRUG: SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
DRUG: SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
DRUG: Placebo + paclitaxel + cisplatin/carboplatin ± BP102

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.